How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.

Journal Article (Journal Article)

Prostate-specific antigen (PSA) screening remains the mainstay for early detection of prostate cancer. Although PSA is a nonspecific prostate cancer biomarker, its specificity for high grade prostate cancer can be enhanced by pre-biopsy liquid biomarkers including the Exosome Dx Prostate IntelliScore (EPI) test. EPI is a stand-alone urine genomic test that measures 3 exosome-derived gene expression signatures without the need for digital rectal examination (DRE) or inclusion of standard of care parameters in the test algorithm. EPI has broad clinical utility as a risk stratification tool for clinically significant high grade prostate cancer in men considering diagnostic prostate biopsy (MRI-targeted and systematic biopsy). During the COVID-19 pandemic, the EPI At-Home Collection Kit was introduced and quickly became an important component of tele-urology. The EPI test has emerged as a prioritization tool for primary care referral to urologists and for prostate biopsy scheduling. EPI provides an objective and actionable genomic risk assessment tool for high grade prostate cancer and is a critical part of the informed decision-making regarding biopsy (targeted, systematic or both) in both urology and primary care practices.

Full Text

Duke Authors

Cited Authors

  • Moul, JW; Sant, GR

Published Date

  • August 2022

Published In

Volume / Issue

  • 29 / 4

Start / End Page

  • 11224 - 11230

PubMed ID

  • 35969726

International Standard Serial Number (ISSN)

  • 1195-9479


  • eng

Conference Location

  • Canada